← Leaderboards
Jevon Cutler
Dana-Farber Cancer Inst
$711,818
Attributed
$711,818
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249K · FY2020–25$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$711,818 · 3
By mechanism
K99$259,200 · 1
R00$249,000 · 1
F32$203,618 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Richard M Stone$3,984,410
- Kenneth C Anderson$25,995,373
- Benjamin Levine Ebert$26,802,844
- Birgit Knoechel$3,667,430
- Dharminder Chauhan$981,987
Others in their field
Other Emerging Leaders on “Programs”
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$348,328,584
- Lynn Briscoe · Leidos Biomedical Research, Inc.$312,382,073
- Chanza Baytop · Westat, Inc.$271,217,917
Research focus
ProgramsPlayGene ExpressionMeninMll GenePharmaceutical PreparationsAcute Myelocytic LeukemiaExperimental StudyIkaros ProteinMass Spectrum AnalysisMethyltransferaseAcute Myeloid Leukemia CellOncogenicPatient-Focused OutcomesCell LineChimeric ProteinsBindingChromatinGeneticGenetic TranscriptionImmunoregulationLeukemiaBiologyProtein Degradation
Grant awards (6)
Targeting Menin Protein Stability In AML$249,000
R00 · FY2025 · CA · contact PI
Targeting Menin Protein Stability In AML$129,600
K99 · FY2024 · CA · contact PI
Targeting Menin Protein Stability In AML$129,600
K99 · FY2023 · CA · contact PI
Defining IKZF1/IKAROS as an oncogene and therapeutic target in MLL-r AML$72,302
F32 · FY2022 · CA · contact PI
Defining IKZF1/IKAROS as an oncogene and therapeutic target in MLL-r AML$66,390
F32 · FY2021 · CA · contact PI
Defining IKZF1/IKAROS as an oncogene and therapeutic target in MLL-r AML$64,926
F32 · FY2020 · CA · contact PI